TNF and rheumatoid arthritis: With further study, the myobundle system has the potential to directly inform how RA pharmacotherapies and combinations thereof impact skeletal muscle (e.g., changes in myobundle force production with tumor necrosis factor-alpha inhibitor versus Janus kinase inhibitor therapy versus combinations).